CIHR-GSK Chair in Paediatric Clinical Pharmacology
Dr. Michael Rieder is a clinical pharmacologist and professor whose research involves studying mechanism(s) of serious, adverse drug reactions, drug safety in children, optimal drug therapy in acute care settings, and steroid biology.
Through his Drug Safety Laboratory, Dr. Rieder has developed a number of novel assays for drug safety and point of care evaluation of food safety. The overarching goal of Dr. Rieder's research is to understand why drugs react differently based on variables such as age, genetic background, co-morbid diseases, and other drugs.
Dr. Rieder qualified in Medicine at the University of Saskatchewan and after training in Paediatrics at Children's Hospital of Michigan/Wayne State University trained in Emergency Paediatrics and Paediatric Clinical Pharmacology at the Hospital for Sick Children as well as completing a Ph.D in Biochemical Pharmacology at the University of Toronto. He joined the faculty at the University of Western Ontario/Children's Hospital of Western Ontario in 1988.
Dr. Rieder holds the CIHR-GSK Chair in Paediatric Clinical Pharmacology at Western and is a Distinguished University Professor in the Departments of Paediatrics, Physiology & Pharmacology and Medicine as well as a Scientist at Robarts Research Institute and the Children's Health Research Institute. Dr. Rieder has been awarded a number of national and international awards including the Leon Goldberg Young Investigator Award from the American Society for Clinical Pharmacology and Therapeutics, the Senior Investigator Award from the Canadian Society of Clinical Pharmacology, the Academic Leadership Award in Clinical Investigation from the Paediatric Chairs of Canada and the Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics from the Pediatric Pharmacy Advocacy Group.
Dr. Rieder joined the Department of Paediatrics and Children's Hospital in 1985. He obtained his MD at the University of Saskatchewan in 1980 and his Ph.D. at the University of Toronto in 1992. His paediatric resident training was at the Children's Hospital of Michigan and he completed fellowships in Paediatric Clinical Pharmacology and Paediatric Emergency Medicine at the Hospital for Sick Children in Toronto.
Dr. Rieder is a Professor with the Department of Paediatrics, Physiology and Pharmacology and Medicine at Schulich Medicine & Dentistry, Western University. He is the Head of the Division of Paediatric Clinical Pharmacology and is a Scientist at the Robarts Research Institute. He is a member of the Drug Therapy Committee of the Canadian Paediatric Society and is a member of the Executive of the Canadian Society of Pharmacology and Therapeutics. He has served as a consultant to Health Canada, the NIH, the MRC and the Canadian College of Academies. Dr. Rieder's research focuses on drug safety and adverse drug reactions as well as on optimal therapeutics in children. This includes studying genetic variations and their impact on drug efficacy and safety and the mechanisms of drug hypersensitivity. As well, Dr. Rieder's laboratory has developed a number of novel assays for the assessment for drug and food safety.
Dr. Rieder has been the recipient of many awards including the 1994 and 1996 Young Investigator of the Year for the Canadian and American Societies of Clinical Pharmacology, the Senior Investigator Award of the Canadian Society of Clinical Pharmacology and the Academic Leadership Award in Clinical Investigation from the Paediatric Chairs of Canada. Other distinguished awards include the Harvard Macy Scholar Award, the Douglas Bocking Award, several Teacher of the Year Awards, Fellowships from the Royal Colleges of Physicians and Surgeons of Glasgow and Edinburgh, a Distinguished University Professor award at Western and the Yaffe Lifetime Achievement Award from the Pediatric Pharmacy Advocacy Group. He holds the CIHR-GSK Chair in Paediatric Clinical Pharmacology, the only endowed Chair in Paediatric Clinical Pharmacology in Canada.
Why I Became a Scientist
Growing up in a family of pharmacists I soon appreciated that while there are a lot of medications available there are also lots of questions about how best to use them safely and effectively. When I became a paediatrician I quickly realized that this is even more the case for children, in that there are many more therapeutic questions than there are answers. My goal in research is to understand sources of variability in human drug response so that we can provide the safe and effective therapy – the right drug at the right dose at the right time for the right patient.
Research Summary
Our research program is an integrated approach to common and important problems in drug safety which draws on the skills of a talented and multi-disciplinary team to understand how the sources of variability in human drug response – which include variables such as age, genetic background, co-morbid diseases and other drugs – can result in patients tolerating therapy or in patients developing serious adverse drug reactions (side effects). Our laboratory, the Drug Safety Laboratory, is the core validation laboratory for a national network of drug safety researchers, the Canadian Pharmacogenomic Network for Drug Safety, and in pursuit of these questions with respect to commonly used drugs such as antibiotics or important therapeutic agents such as cancer chemotherapy we work with collaborators and fellow research across Canada and internationally.
Research Questions
How do serious adverse drug reactions evolve and what are the determinants in who develops or does not develop a serious drug side effect?
Serious drug side effects can carry with them a significant risk of death or disability. Our research has the potential to allow for rapid diagnosis of serious drug side effects and for planning of therapies to reduce the consequences of these side effects.
What are the genetic determinants of serious adverse drug reactions and how can these be used to guide therapy?
The ability to predict which patients are and are not at risk for serious side effects would be a major advantage for health care workers and patients, especially in the setting of serious diseases such as cancer. We hope to able to identify the genetic determinants of serious drug side effects and use this knowledge to develop guidelines that can change how patients are cared for in pursuit of our goal of optimal safe and effective drug therapy.
Can we apply our knowledge of biochemistry and immunology to develop state of the art diagnostic platforms that can be used at point of care?
This development of point of care diagnostic approaches will provide for rapid and accurate diagnosis of important and serious diseases. The application of this knowledge to the food safety sector has direct and immediate implications in reducing the spread of and burden from food-borne disease.
Research Interest Area: Children's health
Research Overview: Paediatric Clinical Pharmacology; Adverse Drug Reactions; Immunopharmacology; Patient Safety; Emergency Paediatrics; Pharmacology Education
×
About Michael Rieder
Dr. Michael Rieder is a clinical pharmacologist and professor whose research involves studying mechanism(s) of serious, adverse drug reactions, drug safety in children, optimal drug therapy in acute care settings, and steroid biology.
Through his Drug Safety Laboratory, Dr. Rieder has developed a number of novel assays for drug safety and point of care evaluation of food safety. The overarching goal of Dr. Rieder's research is to understand why drugs react differently based on variables such as age, genetic background, co-morbid diseases, and other drugs.
Dr. Rieder qualified in Medicine at the University of Saskatchewan and after training in Paediatrics at Children's Hospital of Michigan/Wayne State University trained in Emergency Paediatrics and Paediatric Clinical Pharmacology at the Hospital for Sick Children as well as completing a Ph.D in Biochemical Pharmacology at the University of Toronto. He joined the faculty at the University of Western Ontario/Children's Hospital of Western Ontario in 1988.
Dr. Rieder holds the CIHR-GSK Chair in Paediatric Clinical Pharmacology at Western and is a Distinguished University Professor in the Departments of Paediatrics, Physiology & Pharmacology and Medicine as well as a Scientist at Robarts Research Institute and the Children's Health Research Institute. Dr. Rieder has been awarded a number of national and international awards including the Leon Goldberg Young Investigator Award from the American Society for Clinical Pharmacology and Therapeutics, the Senior Investigator Award from the Canadian Society of Clinical Pharmacology, the Academic Leadership Award in Clinical Investigation from the Paediatric Chairs of Canada and the Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics from the Pediatric Pharmacy Advocacy Group.
Dr. Rieder joined the Department of Paediatrics and Children's Hospital in 1985. He obtained his MD at the University of Saskatchewan in 1980 and his Ph.D. at the University of Toronto in 1992. His paediatric resident training was at the Children's Hospital of Michigan and he completed fellowships in Paediatric Clinical Pharmacology and Paediatric Emergency Medicine at the Hospital for Sick Children in Toronto.
Dr. Rieder is a Professor with the Department of Paediatrics, Physiology and Pharmacology and Medicine at Schulich Medicine & Dentistry, Western University. He is the Head of the Division of Paediatric Clinical Pharmacology and is a Scientist at the Robarts Research Institute. He is a member of the Drug Therapy Committee of the Canadian Paediatric Society and is a member of the Executive of the Canadian Society of Pharmacology and Therapeutics. He has served as a consultant to Health Canada, the NIH, the MRC and the Canadian College of Academies. Dr. Rieder's research focuses on drug safety and adverse drug reactions as well as on optimal therapeutics in children. This includes studying genetic variations and their impact on drug efficacy and safety and the mechanisms of drug hypersensitivity. As well, Dr. Rieder's laboratory has developed a number of novel assays for the assessment for drug and food safety.
Dr. Rieder has been the recipient of many awards including the 1994 and 1996 Young Investigator of the Year for the Canadian and American Societies of Clinical Pharmacology, the Senior Investigator Award of the Canadian Society of Clinical Pharmacology and the Academic Leadership Award in Clinical Investigation from the Paediatric Chairs of Canada. Other distinguished awards include the Harvard Macy Scholar Award, the Douglas Bocking Award, several Teacher of the Year Awards, Fellowships from the Royal Colleges of Physicians and Surgeons of Glasgow and Edinburgh, a Distinguished University Professor award at Western and the Yaffe Lifetime Achievement Award from the Pediatric Pharmacy Advocacy Group. He holds the CIHR-GSK Chair in Paediatric Clinical Pharmacology, the only endowed Chair in Paediatric Clinical Pharmacology in Canada.
Why I Became a Scientist
Growing up in a family of pharmacists I soon appreciated that while there are a lot of medications available there are also lots of questions about how best to use them safely and effectively. When I became a paediatrician I quickly realized that this is even more the case for children, in that there are many more therapeutic questions than there are answers. My goal in research is to understand sources of variability in human drug response so that we can provide the safe and effective therapy – the right drug at the right dose at the right time for the right patient.
Research Summary
Our research program is an integrated approach to common and important problems in drug safety which draws on the skills of a talented and multi-disciplinary team to understand how the sources of variability in human drug response – which include variables such as age, genetic background, co-morbid diseases and other drugs – can result in patients tolerating therapy or in patients developing serious adverse drug reactions (side effects). Our laboratory, the Drug Safety Laboratory, is the core validation laboratory for a national network of drug safety researchers, the Canadian Pharmacogenomic Network for Drug Safety, and in pursuit of these questions with respect to commonly used drugs such as antibiotics or important therapeutic agents such as cancer chemotherapy we work with collaborators and fellow research across Canada and internationally.
Research Questions
How do serious adverse drug reactions evolve and what are the determinants in who develops or does not develop a serious drug side effect?
Serious drug side effects can carry with them a significant risk of death or disability. Our research has the potential to allow for rapid diagnosis of serious drug side effects and for planning of therapies to reduce the consequences of these side effects.
What are the genetic determinants of serious adverse drug reactions and how can these be used to guide therapy?
The ability to predict which patients are and are not at risk for serious side effects would be a major advantage for health care workers and patients, especially in the setting of serious diseases such as cancer. We hope to able to identify the genetic determinants of serious drug side effects and use this knowledge to develop guidelines that can change how patients are cared for in pursuit of our goal of optimal safe and effective drug therapy.
Can we apply our knowledge of biochemistry and immunology to develop state of the art diagnostic platforms that can be used at point of care?
This development of point of care diagnostic approaches will provide for rapid and accurate diagnosis of important and serious diseases. The application of this knowledge to the food safety sector has direct and immediate implications in reducing the spread of and burden from food-borne disease.
Research Interest Area: Children's health
Research Overview: Paediatric Clinical Pharmacology; Adverse Drug Reactions; Immunopharmacology; Patient Safety; Emergency Paediatrics; Pharmacology Education
| Present | CIHR-GSK Chair in Paediatric Clinical Pharmacology, Western University | |
|
|
||
| Present | Professor, Western University ‐ Department of Physiology and Pharmacology | |
|
|
||
| Present | Professor, Western University ‐ Department of Medicine | |
|
|
||
| Present | Scientist, Lawson Health Research Institute ‐ Children's Health Research Institute (CHRI) | |
|
|
||
Disciplines
Research Interests
| 1985 - 1992 | Ph.D, University of Toronto | |
|
|
||
| 1980 - 1983 | FAAP, Pediatric Resident, Wayne State University | |
|
|
||
| 1975 - 1980 | MD, University of Saskatchewan | |
|
|
||